ArticleBMC cancer2025
PSMA5 as a modulator of glioblastoma senescence and prognosis.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Putative glioblastoma origin-like cells in the subventricular zone: isolation and characterization.Experimental & molecular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveThe present study aimed to construct a tumor risk prognosis model and explore the role of PSMA5 in glioblastoma (GBM), focusing on its association with cellular senescence and its potential as both a prognostic biomarker and therapeutic target.
methodsData from the DepMap and Cellage databases were integrated to develop a risk prognosis model, and were refined and evaluated using LASSO and Cox regression analyses. PSMA5 expression in GBM was analyzed via bioinformatics methods and validated in cell lines. Functional experiments using U87 and U251 cells subjected to PSMA5 overexpression and knockdown were conducted to assess changes in proliferation, senescence, cell cycle, DNA damage and associated protein expression. Additionally, a subcutaneous tumor model in immunodeficient mice was used to evaluate tumor growth and analyze tissue characteristics.
resultsThe model identified 5 key genes and demonstrated strong predictive accuracy, with high-risk patients exhibiting significantly shorter survival times. PSMA5 expression was notably elevated in GBM tissues and cell lines compared with normal controls and associated with clinical features. Functional assays revealed that PSMA5 regulates GBM cell proliferation, invasion and migration, while its knockdown induced cellular senescence, characterized by increased β-galactosidase activity, disrupted cell cycle progression and DNA damage. In vivo studies confirmed that PSMA5 overexpression significantly accelerated tumor growth and was widely distributed within tumor tissues.
conclusionThe proposed model is reliable, and PSMA5 plays a critical role in GBM progression by influencing tumor cell behavior and promoting growth. As both a prognostic biomarker and a therapeutic target, PSMA5 offers valuable insights for advancing GBM research and treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.